A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of VS-6766 monotherapy or VS-6766 in
combination with defactinib in subjects with recurrent Non-small cell lung cancer.